Synnovation registers Phase 1 trial of SNV1521 with Revolution Medicines' daraxonrasib
New pancreatic cancer study pairs Synnovation's PARP inhibitor with a RAS inhibitor from collaborator Revolution Medicines.
This week brought a single new registry entry for Synnovation Therapeutics.
- Synnovation Therapeutics has registered NCT07756281, a Phase 1 dose-escalation and expansion study combining its oral drug SNV1521 with the RAS-targeted therapy daraxonrasib in people with pancreatic cancer that cannot be removed by surgery or has spread1. The trial is looking to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer1, with an estimated enrollment of 40 participants and status listed as not yet recruiting. Revolution Medicines, Inc. is named as a collaborator on the study.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.